Nathalie Fagniez Selected Research

tusamitamab ravtansine

1/2023	Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens.
1/2022	Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate.
1/2022	Covariate analysis of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate, based on first-in-human study.
1/2017	Translational Model-Based Strategy to Guide the Choice of Clinical Doses for Antibody-Drug Conjugates.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nathalie Fagniez Research Topics

Disease

4	Neoplasms (Cancer) 01/2023 - 01/2017
1	Keratitis 01/2023
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2023

Drug/Important Bio-Agent (IBA)

4	tusamitamab ravtansineIBA 01/2023 - 01/2017
1	Transaminases (Aminotransferases)IBA 01/2023
1	AlbuminsIBA 01/2022
1	Immunoconjugates (Immunoconjugate)IBA 01/2022